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The vif gene of human immunodeficiency virus type 1 (HIV-1) is required for efficient infection of primary
T lymphocytes. In this study, we investigated in detail the role of vif in productive infection of primary
monocyte-derived macrophages (MDM). Viruses carrying missense or deletion mutations in vif were con-
structed on the background of the monocytotropic recombinant NLHXADA-GP. Using MDM from multiple
donors, we found that vif mutants produced in complementing or partially complementing cell lines were
approximately 10% as infectious as wild-type virus when assayed for incomplete, complete, and circularized
viral DNA molecules by quantitative PCR amplification or for viral core antigen p24 production by enzyme-
linked immunosorbent assay. We then determined the structure and infectivity of vif mutant HIV-1 by using
MDM exclusively both for virus production and as targets for infection. Biosynthetic labeling and immuno-
precipitation analysis of sucrose cushion-purified vif-negative HIV-1 made in MDM revealed that the virus had
reduced p24 content compared with wild-type HIV-1. Cell-free MDM-derived vif mutant HIV-1 was infectious
in macrophages as determined by the synthesis and maintenance of full-length viral DNA and by the produc-
tion of particle-associated viral RNA, but its infectivity was approximately 2,500-fold lower than that of
wild-type virus whose titer was determined in parallel by measurement of the viral DNA burden. MDM infected
with MDM-derived vif-negative HIV-1 were able to transmit the virus to uninfected MDM by cocultivation,
confirming the infectiousness of this virus. We conclude that mutations in vif significantly reduce but do not
eliminate the capacity of HIV-1 to replicate and produce infectious progeny virus in primary human macrophages.
Human immunodeficiency virus type 1 (HIV-1) productively
infects human cells of distinctly different biology and has
evolved replication strategies tailored to these specific cell
types. Investigation of HIV-1 infection of its principal target,
CD4-bearing T lymphocytes, led to the designation of certain
genes as essential, including the canonical retroviral structural
genes gag, pol, and env and the regulators of gene expression
tat and rev (19). The accessory genes vpu, vpr, and nef are
dispensable for infection of peripheral blood lymphocytes
(PBL) in culture (1, 3, 12, 43, 47, 49), although nef appears to
be an essential gene for pathogenic infection of adult monkeys
by the closely related virus simian immunodeficiency virus
(SIV) (25). The status of vif is ambiguous. In certain trans-
formed T cells, vif mutations do not affect virus infection (14,
16, 34, 38, 40, 42, 45); however, the same mutants are severely
impaired in replication in PBL (1, 11, 17, 24, 28, 36, 45). In T
cells, Vif acts after viral DNA and RNA synthesis (5, 6, 11, 40,
45) during the assembly of infectious progeny virions (16, 22,
34, 36, 45). Studies from this laboratory showed that Vif is
required in PBL during processing of the Gag precursor pro-
teins or their incorporation into virions destined for export,
because vif-negative virions produced by PBL carry unproc-
essed Gag and little mature p24 (36). vif-negative viral particles
produced by nonpermissive transformed T cells also contain
high levels of immature Gag proteins (6) and have aberrantly
packed viral cores as shown by electron microscopy (22), sim-
ilarly localizing the defect to the Gag composition of virions.
Other studies indicate that vif-negative virions carry reduced
amounts of gp120 (34). The defective virions produced in the
absence of vif by PBL and other nonpermissive cells are sig-
nificantly less infectious than is wild-type virus (6, 14, 16, 36, 40,
42, 45), which has been attributed to impairments in the early
phases of virus replication, preceding or including viral DNA
synthesis (6, 11, 40, 45).
Most of the information regarding the action of Vif has been
obtained in studies of infection of established T-cell lines or
PBL, whereas little is known about the role of Vif in macro-
phage infection. The HIV-1 life cycle in macrophages differs in
many respects from that in T cells. The process of viral DNA
synthesis has been found to be slower in macrophages than in
PBL in some studies (8, 31) but not others (20); this discrep-
ancy may result from limiting nucleoside pools in macrophages
(31). Generally, HIV-1 protein synthesis is also less efficient in
macrophages than in PBL (3, 9, 46), and there is evidence that
virus may bud into intracellular vesicles as well as into the
extracellular space (32). Several viral functions are required
for productive HIV-1 infection of macrophages but dispens-
able in PBL; for example, an intact nuclear localization signal
in gag or an intact vpr gene is required for nuclear entry of viral
DNA (21, 44); in addition, vpr has been reported to be both
essential and dispensable for macrophage infection (3, 10, 24)
and vpr or vpu is required for viral protein production in
macrophages (47).
* Corresponding author. Mailing address: Molecular Virology Lab-
oratory, St. Luke’s/Roosevelt Hospital Center, 432 W. 58th St., New
York, NY 10019. Phone: (212) 582-4451. Fax: (212) 582-5027. Elec-
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The studies of the role of vif in macrophages have been
confined to evaluation of viral p24 or reverse transcriptase
production (17, 24, 28, 45), with the overall conclusion being
that mutations in vif incapacitate HIV-1 in macrophages. The
site of this restriction and the progress of HIV-1 infection in
macrophages are unknown. In this study, we have investigated
the efficiency of vif-negative HIV-1 infection of macrophages,
evaluating products of both the early and late stages of the
virus life cycle and the synthesis of infectious progeny virus. In
contrast to earlier studies (17, 24, 28, 45), we show that vif-
negative HIV-1 can establish stable infection of macrophages
and produces both viral DNA and protein. vif-negative HIV-1
produced by macrophages is itself infectious to macrophages,
albeit at a low level. We conclude that vif is a modulator but
not a requirement of HIV-1 infection of the natural target
cells, macrophages. These findings also imply that vif-negative
viruses may establish chronic, attenuated infection in vivo.
MATERIALS AND METHODS
Cells. Human monocytes were isolated by elutriation from blood collected
from healthy, HIV-1-negative donors and were cultured in Dulbecco’s modified
Eagle’s medium with 10% AB1 human serum and 10% giant cell tumor condi-
tioned medium (Sigma, St. Louis, Mo.), antibiotics, and glutamine. More than
95% of cells were nonspecific esterase positive. Monocytes were allowed to
adhere and differentiate to monocyte-derived macrophages (MDM) for 5 to 7
days prior to infection with cell-free HIV-1. The human rhabdomyosarcoma cell
line RD (41) was cultured as a monolayer in Dulbecco’s modified Eagle’s me-
dium with 10% fetal bovine serum and antibiotics. The human T-cell leukemia
lines SupT1 (37) and CEM (15) were cultured in RPMI 1640 with 5% fetal
bovine serum and antibiotics.
DNA constructions. To generate macrophage-tropic vif mutant HIV-1, we
used plasmids encoding full-length infectious HIV-1; these plasmids have been
described previously. vif regions were derived from pN1T-A (35), which carries
an intact vif gene; pN1T-E (35), which carries a 35-bp deletion in vif; and pM4,
in which both cysteine codons have been changed to leucine codons by site-
directed mutagenesis (26). The macrophage-tropic HIV-1-encoding pNL-
HXADA-GP provided the proviral cassette and is composed of sequences from
NL4-3, HXB-2, and ADA (46). To construct macrophage-tropic vif mutants, we
replaced the 621-bp NdeI-EcoRI fragment in pGP with the corresponding frag-
ment from pN1T-A, pN1T-E, or pM4. This produced three new recombinants:
AGP, carrying the intact vif coding region; EGP, carrying a deletion in vif; and
M4GP, carrying the missense Cys-to-Leu replacements (Fig. 1A). The amino
acid sequences of their Vif polypeptides are shown in Fig. 1B.
HIV-1 stocks and infection. Virus stocks were prepared by calcium phosphate-
mediated transfection (2) of RD cells or by infection of SupT1 cells with RD
cell-derived virus. Cell supernatants were clarified by low-speed centrifugation,
and the viral particles were concentrated by centrifugation at 12,000 3 g, quan-
tified by enzyme-linked immunosorbent assay for the core antigen p24 by using
the HIV Ag kit (Coulter, Hialeah, Fla.), and frozen in aliquots at 2808C until
use. MDM were infected with 0.004 to 1.0 pg of p24 per cell, and SupT1 cells
were infected with 0.5 pg of p24 per cell, as indicated below. In our hands, 0.5 pg
of viral p24 per cell is equivalent to a multiplicity of infection of 1 as determined
in SupT1 cells for both wild-type (wt) and vif mutant viruses. Infection was
monitored by measurement of p24 in cell supernatants by using the HIV Ag kit
with or without measurement of viral DNA synthesis by PCR, as described
below. For evaluation of transmission by cocultivation 26 days after primary
infection, MDM were harvested by gentle scraping, counted, and replated as
20,000, 4,000, or 800 infected cells supplemented with 106 uninfected MDM. For
experiments involving PCR, virus stocks were resuspended in phosphate-buff-
ered saline at 107 pg of p24 per ml, filtered through 0.45-mm-pore-size filters, and
treated with type II bovine pancreatic DNase (Sigma) at 4,000 U/ml in 10 mM
MgCl2–9 mMNaCl for 1 h at 378C. Except for the systems in which the cells were
incubated with DNase-treated virus for 1 h at 48C and then analyzed by PCR to
determine the extent of carryover viral DNA in virions, all infections were
initiated by incubating the virus with target cells for 2 h at 378C; unfused virions
were then washed off, and incubation was continued under standard condition as
described above.
PCR amplification of viral sequences. At the time points indicated below,
MDM were harvested for PCR by gentle scraping and centrifugation at 200 3 g.
After two washes in phosphate-buffered saline, dry cell pellets were frozen at
2808C until the completion of the experiment, at which time all the samples were
processed in parallel. Lysates were prepared by resuspending the cell pellets in
equal volumes of solution A (10 mM Tris [pH 8.3]; 100 mM KCl, 2.5 mMMgCl2)
and solution B (10 mM Tris [pH 8.3], 2.5 mM MgCl2, 1% Tween, 1% Nonidet
P-40, 60 mg of proteinase K per ml) to a final concentration of 5,000 cell
equivalents per ml, followed by incubation at 558C for 1 h and at 958C for 15 min.
PCR was performed under standard conditions (7, 33). In brief, 2 ml of the cell
lysate (equivalent to 10,000 cells) was mixed in 25 ml of buffer consisting of 10
mM Tris (pH 9.0), 50 mM KCl, 1.5 mM MgCl2, 0.2 mM deoxynucleoside
triphosphates, 0.2 to 0.6 mmol of each primer, and 2.5 U of Taq polymerase
(Perkin-Elmer Cetus, Norwalk, Conn.) and amplification was performed for 30
to 40 cycles of 948C for 1 min, 558C for 1 min, and 728C for 1 min followed by a
final extension at 728C for 15 min. Cell equivalents in lysates were estimated by
amplification of the cellular b-globin gene as described previously (4) and den-
sitometry of the PCR products; the cell lysates were accordingly equalized for
amplification of HIV-1 DNA. Three sets of primer pairs were used for amplifi-
cation of different regions of the HIV-1 genome; these corresponded to incom-
plete molecules, complete linear molecules, or 2-LTR circular molecules, respec-
tively. Map positions are reported in reference to the NL4-3 genome (29). The
strong-stop region was amplified with primers M667 and AA55 (48), which
amplify a region of 140 bp. Full-length HIV-1 DNA was detected with the primer
pair M667 and M661 (48), which produce a fragment of 200 bp. The radiolabeled
probe for both products was M669 (48). 2-LTR circular DNA was amplified with
the primers LTR 566 (59GTCTGTTGTGTGACTCTGGT 39), corresponding to
positions 9641 to 9660 in the 39 long terminal repeat (LTR), and LTR 9170 (59
CTGTCAATCAGGGAAGTAGC 39), corresponding to positions 67 to 86 in the
59 LTR and positions 9151 to 9170 in the 39 LTR; this amplification yielded a
product of 155 bp, which was detected with the hybridization probe LTR 591 (59
GAGATCCCTCAGACCCTTTTAGTCAGTGTG 39), corresponding to posi-
tions 9666 to 9695. To confirm the presence of the 35-bp deletion in vif DNA in
EGP-infected cells, the vif region was amplified with primers VF5071 and
VF5411 and probe VF5282 as previously described (40). Probe VF5161 (59
GACATCACTATGAAAGCCCTC 39), corresponding to positions 5161 to
5181, which are within the 35-bp region deleted in the EGP genome, was used to
confirm the absence of contaminating AGP genome. Blotting, transfer, hybrid-
ization, and autoradiography were performed by standard techniques (2). Linear
HIV-1 DNA was quantified by densitometry with reference to PCR products of
a standard curve of graded numbers of 8E5 cells which contain one copy of viral
DNA per cell. The copy number of the 2-LTR region was estimated by densi-
tometry in comparison with PCR products of graded numbers of acutely infected
CEM cells. To permit reliable quantitation of viral DNA in infection kinetics
FIG. 1. Schematic map of proviral DNA constructions. (A) Map of the pa-
rental molecular clones NLHXADA-GP (solid bars), N1T-A (stippled bars) and
N1T-E (hatched bars) and the new recombinants generated from them. (B)
Amino acid sequences of Vif deduced from the nucleotide sequences. Dots
indicate identity, and dashes indicate deletions.
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experiments, in which virus expression ranges widely, after initial amplification
and gel analysis as described above, samples with signals above the linear range
of the standard curve were diluted and rerun along with other samples. The
dilution factor is marked in the figures when appropriate.
Reverse transcriptase PCR for the detection of HIV-1 RNA. Virions were
isolated from culture supernatants by centrifugation at 100,0003 g for 1 h at 48C.
RNA was isolated from HIV-1-infected MDM or from virions by using Trizol
(Gibco-BRL, Gaithersburg, Md.) as specified by the manufacturer. cDNA syn-
thesis was conducted with the Superscript RT kit (GIBCO-BRL) and the down-
stream primer SK39 (33), the gag region was amplified with the primer pair SK38
and SK39 (33), and the PCR product was detected with 32P-labelled probe SK19
(33). The reverse transcriptase PCR product from 2 3 104 cells or from super-
natants of 2.5 3 105 cells was loaded per lane.
Metabolic labelling and immunoprecipitation.MDM were infected with AGP
or EGP at 0.5 pg per cell for 2 h, labelled with [35S]methionine-[35S]cysteine for
20 h at 16 days postinfection, and harvested or, for pulse-chase experiments,
further incubated for 48 h in standard medium before being harvested. To isolate
virions, cell supernatants were layered onto 15% sucrose and centrifuged at
100,000 3 g at 48C for 2 h. The pellet was lysed in 20 mM Tris (pH 8.0)–150 mM
NaCl–0.2 mM ethylene glycol-bisb-aminoethyl ether)-N,N,N9,N9-tetraacetic acid
(EGTA)–0.2% sodium azide–0.2% sodium dodecyl sulfate (SDS)–0.2% Nonidet
P-40–1 mM iodoacetamide–10 mg of aprotinin per ml–10 mg of leupeptin per
ml–1 mM pepstatin A–1 mM phenylmethylsulfonyl fluoride and frozen at2808C
until analysis. Immunoprecipitation was performed under standard conditions
with the mouse monoclonal antibody AG3.0, kindly provided by J. Allan, which
binds to p55Gag, p24, and processing intermediates. Briefly, lysates were pre-
cleared by incubation with mouse immunoglobulin G and then exposed to AG3.0
for 2 to 3 h at 48C, and antibody-bound material was collected with protein
G-Sepharose (Pharmacia, Piscataway, N.J.) by centrifugation at 10,000 3 g for
2.5 min. The supernatant was discarded, the beads were washed in 20 mM Tris
(pH 8.0)–150 mM NaCl–0.2% Nonidet P-40 three times, and the bound material
was eluted from the beads with electrophoresis sample buffer and was frozen at
2208C until use. Samples were electrophoresed in 12% polyacrylamide contain-
ing SDS, fixed, dried, and exposed to X-ray film by standard methods (2).
Extracellular virions of 4 3 105 AGP-infected cells and 1.6 3 106 EGP-infected
cells were loaded per lane.
RESULTS
vif mutant HIV-1 produced in permissive or semipermissive
cells persistently infects macrophages. For the studies de-
scribed here, we reconstructed the macrophage-tropic HIV-1
clone NLHXADA-GP (46) to generate three isogeneic infec-
tious molecular clones carrying different vif regions (Fig. 1).
AGP carries the intact vif gene of N1T-A (35); EGP carries the
vif deletion of N1T-E and encodes a truncated nonfunctional
Vif (35); and M4GP carries the missense vif mutant of M4 in
which both cysteines are replaced, yielding a full-length non-
functional Vif (26). The three viral clones produced progeny
virus after DNA transfection into RD cells (data not shown)
and caused similarly high levels of infection of SupT1 cells,
which are susceptible to both T-cell-tropic and macrophage-
tropic HIV-1 strains (7). Typical infection profiles of AGP,
EGP, and M4GP in SupT1 cells, obtained by measuring the
kinetics of viral p24 antigen accumulation in culture superna-
tants, are shown in Fig. 2.
Viral stocks produced by transfection into RD cells or by
infection of SupT1 cells were standardized by their p24 content
and were used for infection of MDM. Representative infection
kinetics for AGP, EGP, and M4GP, monitored by the levels of
p24 antigen in culture supernatants, are shown in Fig. 3.
SupT1-derived AGP exhibited a typical macrophage-tropic in-
fection phenotype (7), with p24 production peaking 12 to 15
days after infection at about 100 ng of p24 per ml (Fig. 3A).
Infection with SupT1-derived vif mutants was slower than that
with AGP, but both mutants reached high levels of p24 pro-
duction 15 to 30 days after virus infection (Fig. 3A). In multiple
experiments, the peak p24 production by SupT1-derived vif
mutants in MDM was 30 to 100% of that of AGP (data not
shown). The RD-derived vif mutants also infected MDM, as
determined by the presence of p24 antigen in culture super-
natants, but to lower levels than the SupT1-derived mutants
did (Fig. 3B). The average peak p24 production by these mu-
tants versus wt virus, based on results from nine independent
infections, was 10% (Table 1). In all cases, mutant virus infec-
tion in MDM was persistent, lasting for at least 30 days of
observation (Fig. 3). The observed difference in p24 produc-
tion by SupT1- and RD-derived vif mutants in MDM is con-
sistent with previously reported differences in phenotypic
complementation of the vif defect by tumor cell lines (6, 16, 36,
40, 45). In the next series of experiments, we used RD cell-
derived viruses to minimize the effects of host cell environment
on our stocks of vif-negative virus. We conclude that in con-
trast to previously published studies (17, 24, 28, 45), vif-nega-
tive mutants constructed on the background of a macrophage-
tropic NLHXADA-GP clone can infect macrophages,
resulting in low but persistent production of p24 core antigen.
Efficient viral DNA synthesis during infection of macro-
phages with vif-negative HIV-1 produced in RD cells.We next
determined the progress of vif mutant HIV-1 infection in
MDM by quantitative PCR for the detection of different forms
of viral DNA. We and others have shown previously that in-
efficient infection of T cells with vif-negative virus correlates
with inefficient synthesis of viral DNA (6, 11, 40, 45). MDM
infected with wt and vif-negative viruses produced in RD cells
were evaluated over the course of infection for levels of the
initial reverse transcript strong-stop DNA (18), full-length viral
DNA, and 2-LTR circular DNA, which represents viral DNA
present in the cell nucleus (21, 25). The results are presented
as autoradiograms of amplified DNA (Fig. 4A and 5A) and as
plots of DNA copy numbers estimated from the autoradio-
grams (Fig. 4B and C and Fig. 5B, respectively). As shown in
Fig. 4A and 5A, both wt virus-infected and vif-negative virus-
infected MDM contained all three viral DNA forms; however,
the kinetics of accumulation of each form differed between wt
and mutant infections (Fig. 4B and C and 5B). MDM infected
with any of the three viruses contained about 600 to 900 copies
of strong-stop DNA per 10,000 cells 1 day after infection (Fig.
4B). This indicates both that the mutant and wt viruses entered
MDM and initiated viral DNA synthesis equally well and that
infectious titers of these viruses as measured by the products of
FIG. 2. Production of p24 core antigen by SupT1 infected with wt or vif
mutant HIV-1. The indicated viruses were isolated from RD transfectants and
used to infect SupT1 cells at 0.25 pg of p24 per cell. Extracellular p24 was
monitored at the times indicated after infection.
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first cycle viral DNA synthesis were similar. Although strong-
stop DNA increased 30-fold in wt virus-infected cells, from 700
copies on day 1 to a peak of 22,000 copies on day 6, in the same
period incomplete DNA increased only from 900 to 3,000
copies for EGP-infected cells and from 600 to 800 copies for
M4GP-infected cells (Fig. 4B). Starting 6 days after infection,
the level of full-length DNA was also consistently higher (by
about 10-fold) in wt-infected MDM than in vifmutant-infected
cells (Fig. 4C), consistent with greater p24 production (Fig. 3).
As expected, 2-LTR circular DNA was detected later in infec-
tion than was linear DNA, but the significant difference in
DNA levels between wt and mutant viruses was maintained
(Fig. 5B). These data demonstrate that RD-derived vif-nega-
tive viruses can enter macrophages and complete all the stages
of the viral replicative cycle through DNA entry into the nu-
cleus but that the overall efficiency of viral DNA synthesis is
about 10-fold lower than that of wt virus at the same dose.
There is no evidence that reverse transcription is initiated and
then aborted in vif-negative HIV-1-infected MDM.
Previous studies of vif-negative HIV-1 infection in macro-
phages were usually performed with low doses of virus (17, 24,
28, 45), which may explain the negative results obtained. We
therefore determined the dose response of macrophages to
infection with vif mutant HIV-1 collected from RD cells after
transfection with AGP or EGP DNA. MDM were infected
with 0.5, 0.1, or 0.05 pg of p24 of either virus per cell and were
harvested for PCR 10 days after infection (Fig. 6). As esti-
mated from the standard curve in Fig. 6, MDM infected by
EGP at 0.5 pg of p24 per cell contained roughly 1,000 copies of
viral DNA per 20,000 cells. Reducing the dose of EGP to 0.1
or 0.05 pg of p24 per cell reduced the DNA burden to 50 to 100
copies of viral DNA per 20,000 cells, but viral DNA was clearly
detectable in EGP-infected MDM. No viral p24 was detected
in culture supernatants in these systems (data not shown). In
contrast, MDM infected by AGP at 0.05 pg of p24 per cell
contained about 2,500 HIV-1 DNA copies per 20,000 cells, a
difference of 50 to 100-fold compared with the number of
copies in MDM infected by EGP at the same dose (Fig. 6).
These findings indicate that a low dose of vif mutant virus is
infectious to macrophages, as determined by synthesis of viral
DNA, and that macrophages are infected by vif mutant HIV-1
in a dose-dependent manner.
To confirm that DNA synthesized by vif mutant HIV-1-
infected MDM maintains the vif mutant genotype and that
revertants were not generated during propagation of the virus,
we infected MDM with vif mutant viruses EGP or M4GP
derived from either RD cells or SupT1 cells, amplified viral
DNA from the vif region with primers flanking the 35-bp de-
letion in EGP vif (35) (see also the schematic representation of
the EGP genome in Fig. 1), and used two different probes to
demonstrate the presence of the vif deletion mutant on one
hand and the absence of wt viral DNA on the other (Fig. 7). In
the first procedure, we used probe VF5282, which hybridizes to
a region shared by the deletion mutant (EGP), M4GP, and
AGP (Fig. 7A). Because of the 35-bp deletion in EGP, its
product in this region is 306 bp rather than 341 bp in AGP and
M4GP. No 341-bp DNA product was detected in EGP-in-
fected macrophages (Fig. 7A), indicating a lack of significant
contamination by wt virus in these infections. In the other
approach, we used probe VF5161, which hybridizes to a region
in vif deleted from EGP (Fig. 7B). This approach permits
FIG. 3. Production of p24 core antigen by MDM infected with wt or vif
mutant HIV-1 produced in permissive cells. MDM were infected at 0.5 pg of p24
per cell with the indicated viruses isolated from SupT1 cells (A) or RD cells (B).
Extracellular p24 was monitored at the times indicated after infection.
TABLE 1. Replication of RD-derived vif-negative HIV-1
in macrophagesa
Expt. no.
HIV-1 p24 antigen level (pg/ml) in: p24 level (% of wt)in:
AGP EGP M4GP EGP M4GP
1 27,445 1,559 2,361 5.7 8.6
2 19,990 1,840 1,048 9.2 5.2
3 37,500 2,920 2,650 7.8 7.1
4 68,700 3,055 ND 4.4 ND
5 108,700 11,190 ND 10.3 ND
6 25,800 6,000 ND 23.3 ND
7 84,800 15,790 ND 18.6 ND
8 55,000 4,570 ND 8.31 ND
9 45,400 2,020 ND 4.45 ND
aMDM from nine different donors were infected by AGP, EGP, or M4GP,
and virus replication was monitored by measurement of extracellular p24 levels.
Peak values, attained on days 10 to 21 after infection, depending upon the donor,
are shown. wt, wild-type virus (AGP).
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direct detection of revertant or contaminating wt viral DNA.
As shown in Fig. 7B, EGP-infected macrophages contained no
viral DNA hybridizing with the VF5161 probe, whereas strong
signals were obtained in lysates from cells infected with GP and
M4GP, both of which carry a full-length vif gene. DNA pro-
duced by M4GP-infected MDM is not distinguishable from
that produced by AGP-infected cells by either of the methods
used here. We conclude that our vif-negative viral stocks do
not contain cryptic wt virus revertants and that the infectivity
data presented here reflect exclusively the biological activity of
vif mutant virus in macrophages.
vif mutant HIV-1 completes the virus replicative cycle in
macrophages by producing sedimentable viral particles. To
determine whether p24 detected in culture supernatants of vif
mutant-infected MDM was newly synthesized and was con-
tained in virions, we performed protein analyses. MDM were
infected with GP (the parental vif-positive, macrophage-tropic
virus clone), AGP, or EGP; the cells were metabolically la-
belled; and extracellular particles were purified from cell su-
pernatants by sedimentation through sucrose cushions and an-
alyzed by immunoprecipitation with anti-Gag antibodies and
gel electrophoresis (Fig. 8). After 20 h of labeling, MDM
infected by wt virus infected produced sedimentable material
that contained high levels of newly synthesized p24. EGP-
infected cells produced about 10-fold less particle-associated
p24 (Fig. 8). As expected, a chase for 48 h reduced the levels
of particle-associated p24, but the AGP/EGP p24 ratio re-
mained the same (Fig. 8). Thus, the lifetimes of particle-asso-
ciated wt and vif mutant p24 are similar. We conclude that
MDM infected with vif mutant macrophage-tropic HIV-1 pro-
duce sedimentable particles similarly to wt virus but with lower
efficiency.
FIG. 4. Synthesis of viral DNA by MDM infected with wt or vif mutant HIV-1 produced in permissive cells. MDM were infected at 0.5 pg of p24 per cell with AGP
(A), EGP (E), or M4GP (M) isolated from RD cells. The cells were incubated at 48C for 1 h (day 0) or at 378C for the times indicated and harvested for PCR as
described in Materials and Methods. (A) Lysates of 10,000 cells or the indicated dilution of 10,000 cells were subjected to PCR for b-globin, strong-stop, or full-length
viral DNA as described in Materials and Methods. (B and C) Autoradiograms were subjected to densitometry, and the copy number per 10,000 cells of strong-stop
DNA (B) or full-length viral DNA (C) was calculated.
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The progeny virus produced by vif mutant HIV-1-infected
macrophages can be rescued by infection of complementing
cells. To determine whether vif mutant HIV-1 produced by
MDM is infectious, we first attempted to infect permissive cells
which complement the vif defect and permit the spread of
mutant virus (16, 40, 45). AGP and EGP produced by infected
MDM were used to infect permissive SupT1 cells at approxi-
mately 0.1 pg per cell, and infection was monitored by mea-
surement of extracellular p24 (Fig. 9). Both viruses replicated
in SupT1 cells, although EGP infection lagged behind AGP
infection (Fig. 9). This contrasts with the infection of SupT1
cells by RD-derived AGP and EGP (Fig. 2) and probably
reflects the inherent defect in infectiousness of vif-negative
HIV-1 produced by noncomplementing cells like MDM (6, 14,
16, 36, 40, 42, 45). Thus, vif-negative virus produced in MDM
during primary infection contains infectious viral particles
which can be rescued by culture in permissive SupT1 cells.
vifmutant HIV-1 produced in macrophages is infectious but
highly attenuated in primary macrophages. We next analyzed
the infectivity and life cycle of the MDM-derived vif mutant in
its natural host cells, macrophages. We previously reported
that analogous vif mutant lymphotropic HIV-1 virions pro-
duced by PBL have defective Gag protein composition, which
compromises their infectivity, but the biological activity of such
viruses was not fully defined (36). Others reported that vif
mutants made in PBL are noninfectious in PBL (11). In the
experiments described below, we took advantage of the greater
productivity of vif-negative, macrophage-tropic virus in MDM
(Fig. 3 to 5) and the ability to maintain MDM in culture for
longer periods than PBL could be maintained. We infected
MDM with vif mutant M4GP produced by MDM and moni-
tored infection by measuring p24 production (Fig. 10). In this
and the following experiments, the target MDM presumably
are unable to complement vif defects, and thus they offer a
neutral cellular milieu in which to test the biological activity of
MDM-derived vif mutants. MDM were infected in parallel
with M4GP at 0.5 pg of p24 per cell and fivefold dilutions of
AGP as indicated; all virus stocks were produced in MDM
(Fig. 10). M4GP-infected cells had no detectable p24 in culture
supernatants at the time of the expected peak of infection (2 to
3 weeks). The initial p24 readings probably represented grad-
ual shedding of cell-adsorbed virus. In contrast, MDM infected
with the lowest dose of AGP tested, 0.004 pg of p24 per cell,
still produced significant amounts of p24 at the peak of infec-
tion. Thus, on the basis of p24 production, the MDM-derived
vif mutant suffered a decline of at least 2 orders of magnitude
FIG. 5. Synthesis of 2-LTR circular viral DNA by MDM infected with wt or vif mutant HIV-1 produced in RD cells. MDM from the same experiment as shown
in Fig. 4 were subjected to PCR amplification for 2-LTR circular viral DNA. (A) The indicated number of N1T-infected CEM cells was amplified and run in parallel
as a reference. (B) The autoradiogram was subjected to densitometry, and the relative amount of 2-LTR circular viral DNA per 10,000 cells was calculated.
FIG. 6. Virus dose response of vif-negative HIV-1 infection in MDM deter-
mined by synthesis of gag region DNA. MDM were infected with the indicated
doses (in picograms of p24 per cell) of either AGP or EGP and were harvested
10 days after infection for PCR amplification of gag region DNA. As indicated,
lysates from 5- or 10-fold-fewer AGP-infected cells than EGP-infected cells were
loaded per lane to generate signals which fall within the standard curve.
FIG. 7. Preservation of the vif-negative genotype and absence of genotypic
reversion in MDM infected by vif mutant HIV-1. MDM were infected at 0.5 pg
of p24 per cell with AGP, EGP, or M4GP derived from either RD or SupT1 cells,
as indicated. On day 12 after infection, MDM were subjected to PCR for vif as
described in Materials and Methods. Lysates of 2,000 to 4,000 AGP-infected cells
were loaded per lane, and lysates of 10,000 to 40,000 EGP- and M4GP-infected
cells were loaded per lane for comparable detection. The expected sizes of DNA
fragments of wt vif and vif containing the N1T-E deletion are indicated. (A)
Probe VF5282; (B) probe VF5161.
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in its ability to productively infect macrophages compared with
similarly prepared wt virus. These experiments did not exclude
a total loss of infectivity of this “second-generation” vif mutant
virus in MDM.
To determine whether M4GP derived from MDM was ca-
pable of entering and synthesizing viral DNA in noncomple-
menting cells, the infections described in the previous section
were repeated with DNase-treated viruses and viral DNA lev-
els were evaluated by quantitative PCR (Fig. 11). MDM in-
fected with M4GP at 0.5 pg of p24 per cell clearly synthesized
strong-stop viral DNA 24 h after infection but at a level of only
about 50 DNA copies per 10,000 cells, similar to that achieved
with 0.02 pg of p24 of wt virus per cell (Fig. 11) and about
10-fold less than that with RD-derived M4GP 24 h after pri-
mary infection at the same dose (Fig. 4). This result indicates
that macrophage-derived M4GP can enter MDM and initiate
viral DNA synthesis, albeit with significantly lower efficiency
than that of the same virus produced by RD cells. Full-length
HIV-1 DNA was barely detectable at 24 h in M4GP-infected
cells (fewer than 10 copies per 10,000 cells), but both strong-
stop and complete DNA levels increased in these cells to
clearly detectable amounts during the subsequent 25 days of
culture (Fig. 11B and C). Quantitation of full-length viral DNA
copy numbers in infected cells by densitometry (Fig. 11D)
showed that on day 16, which was the peak of infection with
low doses of wt virus (Fig. 10), MDM infected with M4GP at
0.5 pg of p24 per cell contained 20 DNA copies per 10,000 cells
and MDM infected with AGP at a 125-fold-lower dose con-
tained 400 copies per 10,000 cells. By day 26 after infection, the
number of full-length DNA copies in wt virus-infected cells
was similar to or smaller than on day 16 whereas it doubled in
M4GP-infected cells (Fig. 11D). As measured by its ability to
synthesize full-length viral DNA in macrophages 16 days after
infection, the biological titer of the macrophage-derived vif
mutant was about 2,500, or at least 3 orders of magnitude
lower than that of wt virus.
To determine whether the vif-negative DNA made in mac-
rophages was expressed, infected cells and their supernatants
were investigated for the presence of viral RNA. At 26 days
after AGP or EGP infection, total cellular RNA or RNA
present in high-speed centrifugation-derived pellets of culture
supernatants was extracted, treated with DNase, subjected to
reverse transcription, and amplified by PCR for the gag region
(Fig. 12). Cells and sedimented culture supernatants from both
AGP- and EGP-infected macrophages contained HIV-1 RNA,
indicating that viral DNA in these cells was expressed and at
least some of it was secreted to the culture medium as sedi-
mentable particles.
As the most sensitive test of HIV-1 transmissibility, MDM
infected by MDM-produced EGP were cocultivated with a
large excess of uninfected MDM 26 days after primary infec-
tion. Transmission was observed by detection of 12 pg of p24
per ml of culture supernatant 28 days after cocultivation.
Taken together, these analyses indicate that vif-negative HIV-1
made in macrophages is highly attenuated but that it can es-
tablish a slowly spreading infection in its natural host cells.
FIG. 8. Synthesis of viral p24 by MDM infected by wt or vif mutant HIV-1.
MDM were infected and metabolically labeled with [35S]cysteine-[35S]methi-
onine, and cell supernatants were subjected to high-speed centrifugation to
isolate particulate matter, which was then subjected to radioimmunoprecipita-
tion as described in Materials and Methods. MW (kd), molecular mass in kilo-
daltons.
FIG. 9. Infection of SupT1 cells by wt or vif mutant HIV-1 produced in
MDM. MDM were infected as described in Materials and Methods, and cell
supernatants were collected 14 days after infection and used to infect SupT1 cells
at 0.1 pg of p24 per cell. Extracellular p24 was monitored at the times indicated.
FIG. 10. Production of p24 core antigen by MDM infected with wt or vif
mutant HIV-1 derived from MDM. Supernatants were harvested from HIV-1-
infected MDM and were used to infect MDM at the doses indicated in picograms
of p24 per cell. Extracellular p24 was monitored at the times indicated.
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DISCUSSION
We report here that mutations in vif reduce but do not
eliminate the capacity of HIV-1 to replicate and produce in-
fectious progeny virus in primary human macrophages. These
results establish Vif as a potent facilitator but not an absolute
requirement of HIV-1 infection of macrophages. Vif is there-
fore the only auxiliary gene product of HIV-1 required for
efficient replication in both natural target cell types, PBL (1,
11, 17, 24, 28, 36, 45), and macrophages, suggesting that it may
play a pivotal role in HIV-1 replication during natural infection
of humans.
Our conclusions are based on measurement of viral DNA,
protein, or RNA from cells infected by vif mutants derived
from cell lines or directly from infected macrophages. These
results differ from most of the previously published data con-
cerning the extent of impairment of replication of vif mutant
HIV-1 in macrophages (17, 24, 28, 45). One study in which wt
virus infection was poor showed only a sixfold reduction in
protein production in MDM infected by vif mutant HIV-1
derived from Cos cells (45), entirely consistent with our find-
ings reported in Table 1. Two other reports of systems opti-
mized for HIV-1 protein production in MDM (17, 24) and one
of less quantitation by virus rescue (28) indicate a total block to
virus replication by vif mutations. In the former studies, input
virus doses were probably too small to permit analysis of virus
spread from infected to uninfected MDM. We have elaborated
upon this scheme by isolating vif mutant HIV-1 from infected
macrophages and then testing its infectivity in MDM in terms
of dose response, thereby permitting reliable estimates of the
extent of its defects. As we show in Fig. 10, the production of
extracellular viral p24 is undetectable in this format, indicating
a profound block to the synthesis and export of fully mature
virions; these results are entirely consistent with those of the
previous studies. However, we also analyzed the stages of vif-
negative HIV-1 replication preceding virus export and found
that vif mutant HIV-1 produced by MDM is able to complete
viral DNA synthesis (Fig. 11), transcribe viral RNA, and export
it in the form of sedimentable particles (Fig. 12), albeit at a
lower efficiency than wt virus does. Moreover, the vif defect
does not eliminate the production of infectious virus, as shown
by the ability of EGP-infected MDM to transmit virus by cocul-
tivation. Some of the first studies of vif-negative HIV-1 indi-
cated that the virus was more transmissible by cocultivation
than by cell-free virus infection (13, 42), an observation that we
confirm here with virus derived from and replicating in natural
target cells.
Using MDM as targets for infection, we localized the site of
attenuation of vif-negative replication by quantitation of in-
complete, complete, and nuclear forms of viral DNA (Fig. 4
and 5). The ratio of strong-stop to full-length linear viral DNA
is close to 1 at the peak of infection by vif-negative HIV-1,
indicating that reverse transcription is completed efficiently.
However, there is a 10-fold reduction in all forms of viral DNA
in vif-negative virus-infected cells compared with wt virus-in-
fected cells when using virus prepared from partially comple-
menting RD cells. Since the ratio of full-length viral DNA to
nuclear DNA in vif-negative virus- and wt virus-infected cells is
similar, localization of DNA to the nucleus is unaffected by vif
mutations (Fig. 5). The 10-fold reduction in the level of strong-
FIG. 11. Synthesis of viral DNA by MDM infected with wt or vif mutant
HIV-1 derived from MDM. (A to C) MDM from the experiment shown in Fig.
10 were subjected to PCR as described in the legend to Fig. 4. (C) Longer
exposure of selected lanes from panel B to produce signals suitable for densi-
tometry. (D) The autoradiograms were subjected to densitometry, and the num-
ber of full-length viral DNA molecules was calculated.
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stop DNA suggests that the major limitation to the infectivity
of vif-negative virions is their ability to enter cells, uncoat, or
initiate reverse transcription. These defects are consistent with
aberrations in envelope glycoprotein display on particles (34),
in virion architecture (6, 22), or in Gag protein composition
(11, 36), all of which have been attributed to the absence of Vif
during HIV-1 production in nonpermissive cells.
Defects in vif-negative viruses can be masked by cell-depen-
dent complementation during virus replication, and the degree
of complementation differs among cells (6, 16, 45). Comple-
mentation is revealed by the differences in the biological ac-
tivity of vif-negative virus produced by different cells during
infection of noncomplementing cells like MDM. RD cell-de-
rived vif mutant HIV-1 produced complete and circularized
forms of viral DNA and viral p24, all at approximately 10% of
the level produced by wt virus in MDM (Table 1; Fig. 3 and 4).
However, MDM infected by the same dose (in p24) of viruses
produced by MDMwere unable to synthesize p24 (Fig. 10) and
synthesized approximately 2,500-fold less viral DNA than did
wt virus (Fig. 11). Thus, RD cells partially replace vif function
and produce a virus only moderately (10-fold) defective. In
contrast, MDM synthesize virions which are attenuated in in-
fectivity, virions we infer to be representative of vif defects with
little interference from cellular factors. On the basis of these
findings and previous studies from this laboratory (36) and
others (6, 16), we believe that the differences in infectivity of
RD- and MDM-derived viruses may be attributed to differ-
ences in capsid structure. In this view, both cells produce het-
erogeneous vif-negative virions, a minority of virions carry only
p24, and it is this minority which is infectious. Studies with
suboptimal doses of an inhibitor of the HIV-1 protease indi-
cate that a minor component of unprocessed Gag renders
HIV-1 particles noninfectious (23). Previous studies from this
laboratory illustrate that vif-negative particles produced by
PBL carry various amounts of unprocessed Gag and a small
amount of mature p24 but are severely impaired in infectivity
(36).
Unlike studies of other retroviruses, the initial work on
HIV-1 was conducted most often in transformed cells, which
provided the original designation of certain genes as accessory
(19). Recent studies (1, 3, 11, 17, 24, 28, 45) including our own
(36), have refined these definitions by investigating the virus
life cycle in primary lymphocytes and macrophages and have
revealed a greater role for accessory genes than was first pro-
posed. On the basis of the degree of HIV-1 attenuation by
ablation of vif estimated here (3 to 4 orders of magnitude), the
major role of vif in HIV-1 replication in both macrophages and
lymphocytes in culture, and its maintenance in lentiviruses (30)
and in HIV-1-infected persons (39), we propose that vif is a
critical determinant of HIV-1 virulence during natural infec-
tion of humans. Consistent with this proposition, a long-term
survivor of HIV-1 infection was shown recently to harbor virus
carrying multiple mutations in accessory genes, including vif
(27), and one of these mutations was the missense cysteine
replacement described first by this laboratory (26). This work
indicates that vif mutant viruses persist in vivo and are not
pathogenic. The results reported here provide a potential mo-
lecular basis for this chronic, avirulent infection.
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